There could be 2,000 new HIV infections a day across the world and a ten-fold increase in related deaths if funding frozen by ...

In 2021, the 30.7 million beneficiaries accounted for over $2 billion in payments for the 101 generic drugs. Under the ...

The future of HIV care requires balancing scientific advancement with practical implementation. Long-acting antiretroviral ...

People with AIDS also have HIV, as HIV is the first stage of AIDS. Learn about the differences, how the conditions overlap, ...

A research group led by Professor Wei Li from the Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Toho ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=UAE125 ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...